We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research
News

AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research

AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research
News

AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that its research and diagnostic antibody unit AbD Serotec has amended its existing license agreement with Merck & Co., Inc. to include the use of MorphoSys's HuCAL GOLD technology in the field of vaccines.

Under the terms of the agreement, Merck is granted access to HuCAL GOLD for research purposes, with the option to upgrade to MorphoSys's latest proprietary antibody library HuCAL PLATINUM.

MorphoSys's research and diagnostic antibody segment AbD Serotec will receive annual user fees from Merck for access to the HuCAL technology and license fees for clinical monitoring reagents. Further financial details were not disclosed.
 
"We welcome Merck's decision to continue using the HuCAL technology on the research side as a tool to support their vaccine development activities. It is a clear sign of the sustained interest of the pharmaceutical industry in our leading antibody technology," commented Dieter Feger, Senior Vice President and Head of AbD Serotec.

Advertisement